Trials / Recruiting
RecruitingNCT06577519
Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
Efficacy and Safety of Vicagrel in Patients With With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI): a Multi-center, Randomized, Double-blind, Double-dummy , Parallel-controlled, Phase III Trial
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,000 (estimated)
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, randomized, double-blind, double-dummy, parallel-controled, phase III trial, aiming to evaluate the effectiveness and safety of long-term continuous administration of Vicagrel capsules in ACS patients undergoing PCI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vicagrel | Vicagrel loading followed by Maintenance dose |
| DRUG | Clopidogrel | Clopidogrel loading followed by Maintenance dose |
Timeline
- Start date
- 2024-09-06
- Primary completion
- 2026-12-30
- Completion
- 2026-12-30
- First posted
- 2024-08-29
- Last updated
- 2024-10-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06577519. Inclusion in this directory is not an endorsement.